Pfizer revenues continue to depict lacklustre performances due to weak sales of its blockbuster drugs such as Lipitor and Viagra, amongst others. Pfizer's R&D pipeline continues to appear weak, with 11 of its 25 drugs in Phase 3 comprising line extensions. The Wyeth acquisition was completed in October 2009 and Pfizer will start reporting performance from 4Q 09. Wyeth's pipeline is strong but requires significant R&D investment from Pfizer. Moreover, revenues are expected to remain under pressure, exacerbated by Lipitor's patent expiry (starting next year). 38.9% of Pfizer's revenues face patent expiry over next couple of years. Consequently, Pfizer has an upheaval task to rein in the revenue deterioration by focusing on new launches and Wyeth drugs. The company continues to focus on Sutent and Lyrica. Although the long term outlook for both these drugs is positive, with the expected launch of line extensions over the next couple of years; in the medium term these drugs are expected to grow at a modest pace. As the consolidation of Wyeth has begun and the company will report partial performance in 4Q 09, we expect a negative impact on consolidated margins over the medium term. Moreover, patent expiry of blockbuster drugs will have a lasting impact on operating performance. Pfizer has gross margin of approximately 85%, compared to Wyeth's 71%. We continue to expect Pfizer, with Wyeth's consolidation and its low cost sourcing strategies to be able to achieve higher economies of scale, thereby bridging the gap between both companies' gross margins over the next 2 years. Moreover, net margin will be hampered by high interest charges streaming from the increased debt following the Wyeth's acquisition.

From September 2009, the Research Oracle will begin to accept research submissions from readers – whether amateur or professional analysts – from around the globe. To receive notification of the launch and rules, contributors may register now at
http://www.iirgroup.com/researchoracle/researchoracleaward